Product
MEK inhibitor + Hydroxychloroquine + Bevacizumab
1 clinical trial
7 indications
Indication
RAS MutationIndication
Ras Gene MutationIndication
Colorectal Cancer RecurrentIndication
Pancreatic CancerIndication
lung cancerIndication
MelanomaIndication
Refractory CancerClinical trial
New Therapeutic Approaches for Tumors With RAS Gene MutationsStatus: Recruiting, Estimated PCD: 2026-10-01